

BioTime Co-CEO Dr. Michael D. West to Chair Cell Therapy Track at World Precision Medicine Congress USA 2016

November 10, 2016

-Will Also Present at Young Jewish Professionals Life Sciences & Pharmaceuticals CEO Symposium-

ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 10, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that Co-Chief Executive Officer Michael D. West, Ph.D., is participating at two conferences during the week of November 14.

On Monday, November 14, Dr. West is serving as Chairperson for the [Cell Therapy Track](#) at Terrapinn's [World Precision Medicine Congress USA 2016](#). The conference will take place at the Hyatt Regency Washington on Capitol Hill, in Washington, DC. Dr. West is also delivering a talk, "Enhancing Autologous Cell Therapies for the Precision Era," at 5:10 pm Eastern Time.

On Thursday, November 17, Dr. West is delivering a talk on building a successful biotechnology company at the [Young Jewish Professionals \(YJP\) Life Sciences & Pharmaceuticals CEO Symposium](#), November 16 and 17 in Midtown Manhattan. This invitation-only forum features a variety of executives from industry as well as asset management firms. Dr. West's talk will focus on lessons learned from founding Geron, believed to be the first regenerative medicine company, as well as his time as CEO and Chief Scientific Officer of Advanced Cell Technology (later renamed Ocata Therapeutics and acquired by Astellas Pharma earlier this year), and his years with BioTime, which he joined as CEO in 2007 before transitioning to his current Co-CEO role in 2015.

About BioTime

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what the company believes to be the world's premier collection of pluripotent cell assets. The foundation of BioTime's core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. Pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

In addition to the development of therapeutics, BioTime's research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications.

BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on [Twitter](#), [LinkedIn](#), [Facebook](#), [YouTube](#), and [Google+](#).

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: <http://news.biotimeinc.com>.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20161110006544/en/>

Source: BioTime, Inc.

Investor Contact:

EVC Group, Inc.

Matt Haines, 917-733-9297

mhaines@evcgroup.com

or

Media Contact:

Gotham Communications, LLC

Bill Douglass, 646-504-0890

bill@gothamcomm.com